accompanying care, 153
acute demyelinating optic neuritis, 226
acute disseminated encephalomyelitis. See ADEM
acute hemorrhagic leukoencephalitis (AHLE), 192, 208
acute hemorrhagic encephalomyelitis (AHEM), 186
acute necrotizing hemorrhagic leukoencephalitis (ANHLE), 186
acute transverse myelitis (ATM), 243–252
acute interventions, 251
clinical features, 247–248
diagnostic criteria, 243–244
diagnostic evaluation of sudden spinal cord dysfunction, 249–251
differential diagnosis, 249–251
epidemiology, 243
etiology, 244
extraspinal differential diagnosis, 249
immunopathogenesis, 244–246
incidence and prevalence, 243
intraspinal conditions other than ATM, 250
medical treatments, 251
MRI features, 247–248
outcome, 248–249
overlap with MS and related diseases, 244
preceding illness, 246–247
preceding immunisation, 246–247
prognosis, 248–249
rehabilitation, 251–252
risk of development of MS, 244
versus ADEM, 250
versus CIS and MS, 250
versus NMO, 250
work-up, 250
See also transverse myelitis (TM).
Addison’s disease, 175
ADEM (acute disseminated encephalomyelitis)
2007 operational definition, 11
additional therapeutic options, 214–217
antecedents, 184–188
bi- striatal variant, 208
bi-thalamic variant, 208
clinical and biological features, 183–197
clinical distinctions, 185
clinical features, 183–194
clinical presentation, 185
cytokine and chemokine levels, 196
differential diagnosis, 53–54, 186–187
direct CNS infection hypothesis, 196
distinction from CIS and MS, 189–193
distinction from pediatric MS at onset, 4
epidemiology, 21, 183–184
further episodes of demyelination, 187
genetic susceptibility, 196
high-dose corticosteroid treatment, 212–214
incidence and prevalence, 21
intravenous immunoglobulin treatment, 215
IPMSSG definition, 191
laboratory distinctions, 193
laboratory tests, 186
lack of MRI criteria, 14
link with childhood illnesses, 4
link with vaccines, 4
link with viruses, 4
methylprednisolone treatment, 212–214
natural history of the disease, 212
molecular mimicry hypothesis, 194–196
monophasic ADEM, 214–217
MRI features, 202–210
multiphasic ADEM, 15–16, 187–189
neuroimaging findings, 186
neurological distinctions, 185
operational definition, 10
oral prednisone treatment, 212–213
outcome, 187
pathology and immunopathology, 194–196
plasma exchange treatment, 215–217
post-vaccinal form, 194
prognosis, 217–219
recurrent ADEM, 15–16, 187–189
repetition of IV methylprednisolone treatment, 214
risk of developing MS, 193
role of autoantibodies, 196
supportive care, 217
treatment, 212–220
adenoleukodystrophy
differential diagnosis, 66
adult care
transitioning to, 153
age
at onset of pediatric MS, 21–24, 36–39
influence on presentation and relapses, 41
AIDS (acquired immunodeficiency syndrome)
differential diagnosis, 62–63
alemtuzumab, 105
Alexandrov’s disease
differential diagnosis, 67
antibody responses in MS, 162
anti-Sjögren’s syndrome antibody (SS-A), 244
aquaporin-4 (AQP4)
autoimmunity, 255
aspergillosis, 64
ataxia and tremor
symptomatic therapy, 119
autoimmune diseases in families, 172–173
azathioprine
combined with beta interferons, 106–107
B cell responses in MS, 162
Behçet syndrome
differential diagnosis, 61
biology of pediatric MS, 157–164
CSF profiles, 159–160
environmental factors, 162–163
Index

immunobiology, 160–162
importance of better understanding, 157
need for biomarkers of inflammation, 163–164
need for biomarkers of neurodegeneration, 163–164
pathology, 157–159
responses to infectious agents, 162–163
role of vitamin D, 163
birth place
and risk of pediatric MS, 24–25
bladder dysfunction
symptomatic therapy, 121–124
bowel dysfunction
symptomatic therapy, 124
breakthrough disease
definition, 98
management strategies, 98–99
breakthrough therapies, 101–109
alemtuzumab, 105
combination therapies, 106–108
corticosteroids, 105–106
cyclophosphamide, 103–104
daclizumab, 105
drugs approved in other indications, 103–104
goals in pediatric MS, 101
interferon beta and azathioprine, 106–107
interferon beta and glatiramer acetate, 106
interferon beta and methylprednisolone, 106
interferon beta and mitoxantrone, 107
interferon beta and natalizumab, 107–108
lack of data for the pediatric age group, 101
methotrexate, 104
mitoxantrone, 103
monoclonal antibodies, 104–105
mycophenolate mofetil, 104
natalizumab, 102–103
rituximab, 104–105
second-line drugs approved in adult MS, 102–103
Brief Neuropsychological Battery for Children (BNBC), 137
Bruininks-Oseretsky Test of Motor Proficiency-2 (BOT-2), 117
CADASIL
differential diagnosis, 68
Carter effect, 171
celiac disease
differential diagnosis, 68
Charcot, Jean-Martin, 1, 13
chickenpox, 27
childhood ataxia with diffuse CNS hypomyelination
differential diagnosis, 67
Children’s Depression Inventory, 130
Chlamydia pneumoniae infection, 27
chronic recurrent inflammatory optic neuritis (CRION), 234–235
clinical presentation of pediatric MS, 36–45
ADEM-like first attack, 39–41
age at diagnosis, 36–39
age at first attack, 36–39
chronic symptoms, 41–43
classification of clinical features, 36
clinical features, 39–43
clinical outcomes, 43–45
definition of disease onset, 39
duration of clinical observation, 39
encephalopathy, 41
future directions for research, 45
influence of age on presentation and relapses, 41
methodological aspects, 36–39
relapse-related symptoms, 39–41
seizures, 39
upper age limit for pediatric MS, 36–39
clinical vignettes, 6–7
clinically isolated syndrome (CIS), 5
operational definition, 10, 11
CNS lymphoma
differential diagnosis, 65
CNS vasculitis
differential diagnosis, 61
cognitive dysfunction in pediatric MS, 134–141
cognitive profile of pediatric MS, 117
clinical correlates, 134–136
considerations in assessment and interpretation, 138–139
effects of fatigue, 138
effects of pain, 138
effects of psychological distress, 138
factors affecting test performance, 138–139
future research directions, 140–141
impact in school, 147
impacts on functional activities, 139–140
longitudinal course, 136–137
neuropsychological assessment techniques, 137–138
neuropsychological testing, 138–139
particular problems in children, 134
patterns of impairment, 134–136
prevalence, 134–136
profile of cognitive impairments, 134
severity of cognitive impairments, 134
coordination difficulties, 117
evaluation, 117–118
Corticosteroids
breakthrough therapies, 105–106
dosing regimen, 93
mechanism of action, 92
side effects, 93–94
use in adults, 92–93
use in pediatric MS relapses, 92–94
course of pediatric MS, 75–84
development of cognitive problems, 83–84
development of irreversible disability, 80–83
influence of environmental factors, 79–80
influence of genetic factors, 79–80
initial course, 77
limitations of research studies, 75–76
methodological considerations, 75–76
prognosis, 80–84
prognostic factors for disability, 82–83
prognostic factors for secondary progression, 79
recovery after relapses, 79
relapse rate, 78–79
research using case studies, 75
symptom severity at disease onset, 78
time between first and second neurological episodes, 78
time to a secondary progression, 79
time to disability milestones, 80–82
CSF criteria
diagnostic significance, 14–15
CSF profiles in pediatric MS, 159–160
cyclophosphamide, 103–104
cysticercosis
differential diagnosis, 65
cytomegalovirus (CMV), 26, 63
daclizumab, 105
demographics of pediatric MS, 13
depression
evaluation, 130
management, 130
Devic disease. See neuromyelitis optica diabetes (type 1), 175
diagnosis
importance of accurate and early diagnosis, 5
Index

diagnosis of pediatric MS
lack of clear differential diagnosis, 16
prepubertal and postpubertal forms, 16
See also operational definitions
differential diagnosis, 58–70
adrenoleukodystrophy, 66
AIDS (acquired immunodeficiency syndrome), 62–63
Alexander’s disease, 67
Behçet syndrome, 61
CADASIL, 68
celiac disease, 68
childhood ataxia with diffuse CNS hypomyelination, 67
CNS lymphoma, 65
CNS tuberculosis infection, 62
CNS vasculitis, 61
cytisocrisis, 65
fungal infections of the CNS, 64–65
future research directions, 69
globoid cell leukodystrophy, 66
hemoglobinopathies, 68
Henoch-Schoenlein syndrome, 68
herpesvirus infection, 64
hiostiocytopathy, 68–69
HIV (human immunodeficiency virus) infection, 62–63
HTLV (human T-cell lymphotropic virus) infection, 63
infections, 61–65
Kawasaki syndrome, 68
key points, 69
Krabbe’s disease, 66
Langerhans cell histiocytosis, 68–69
leukodystrophies, 66–67
Lyme disease, 64
medication-related MS-like symptoms, 69
metachromatic leukodystrophy, 66
migraine (atypical presentations), 67
mimics of CNS demyelinating disorders in children, 68
mitochondrial disorders, 67
MS-like symptoms caused by toxic substances, 69
Mycoplasma infection, 64
neoplasms, 65–66
neuroborreliosis, 64
neurocysticercosis, 65
neuroarosarcoidosis, 60–61
optic pathway glioma, 65–66
Pelizaeus–Merzbacher disease, 66
polyarteritis nodosa, 68
primary or isolated CNS vasculitis, 61
progressive multifocal leukoencephalopathy, 63
sarcoïdosis, 60–61
scleroderma, 61
Sjögren’s syndrome, 68
Susac syndrome, 68
systemic inflammatory disorders, 58–61
systemic lupus erythematosus (SLE), 58–60
tuberculosis, 62
tuberculous meningitis, 62
vanishing white matter disease, 67
vascular disorders, 67–68
Wegener’s granulomatosis, 68
Whipple’s disease, 64
diffusion tensor imaging (DTI), 54
disease-modifying therapy (DMT), 5, 6, 96–99
breakthrough disease, 98–99
first-line therapies, 96–98
glatiramer acetate, 97–98
interferon beta, 96–97
use in pediatric optic neuritis, 230–231
dissemination in time diagnostic significance, 15–16
emotional health of the child/teen, 151
encephalopathy diagnostic significance, 13
environmental factors in pediatric MS, 26–28, 79–80, 162–163
epidemiology of pediatric MS, 19–29
age at onset, 21–24
birth place, 24–25
chickenpox, 27
Chlamydia pneumoniae infection, 27
demographic characteristics, 21–25
environmental risk factors, 26–28
Epstein-Barr virus infection, 26–27
family history of demyelinating disorders, 25–26
gender ratio, 21
gene interactions, 173
geographic distribution of pediatric MS, 172–173
genetics of pediatric MS, 169–177
autoimmune diseases in families, 172–173
CD226 risk gene, 175–176
CD58 risk gene, 175–176
CLEC16A risk gene, 175–176
epigenetic interactions within the HLA locus, 174–175
EV1-5 risk gene, 175–176
familial risks of MS, 170–172
gene–gene interactions, 173–174
genes versus family environment, 170
IL2RA risk gene, 175–176
IL7R risk gene, 175–176
infectious mononucleosis risk factor, 174
major histocompatibility complex (MHC), 173–175
MHC class I, 175
MHC class II, 173–174
migration studies, 170
molecular genetic studies, 173
MS patient groups, 169–170
neuronal risk genes, 176
non-HLA immune risk gene SNPs, 175–176
role of vitamin D response elements, 174
single gene disorders that mimic pediatric MS, 176–177
genealogic distribution of pediatric MS, 24

© in this web service Cambridge University Press www.cambridge.org
Index

glatiramer acetate combined with interferon beta, 106
disease-modifying therapy, 97–98
globoid cell leukodystrophy
differential diagnosis, 66
Graves' disease, 175
Gross Motor Function Classification System (GMFCS), 117
Guillain-Barré syndrome, 249
Harding’s disease, 176
health-related quality of life in MS, 144–146
heat intolerance
symptomatic therapy, 125–128
hemoglobinopathies
differential diagnosis, 68
hemophagocytic lymphohistiocytosis, 69
Henoch-Schönlein syndrome
differential diagnosis, 68
hepatitis B vaccine, 28
herpes encephalitis, 63
herpes simplex virus (HSV), 26
herpesvirus infection
histiocytosis
differential diagnosis, 68
Hierarchy of Visual Skill Development Model, 114
Historical perspective, 1
Hierarchical visual skill development
model, 114
histiocytosis
differential diagnosis, 68–69
historical perspective, 1–6
historical descriptions of MS, 1
initial reports of pediatric MS, 1–3
nature of demyelinating diseases, 3–4
pediatric MS and ADEM initial events, 4
pediatric MS and leukodystrophies, 3–4
recent increased interest in pediatric MS, 5–6
renewed interest in pediatric MS (1950s), 4–5
HIV (human immunodeficiency virus) infection
differential diagnosis, 62–63
HTLV (human T-cell lymphotropic virus) infection
differential diagnosis, 63
human herpesvirus-6 (HHV-6), 26
immunobiology of MS, 160–162
antibody responses, 162
B cell responses, 162
features of the pediatric immune system, 160–161
T cell responses and studies, 161–162
infections
differential diagnosis, 61–65
infectious agents
role in pediatric MS, 162–163
infectious meningoradiculitis, 249
infectious mononucleosis, 26
risk factor for MS, 174
interferon beta combined with azathioprine, 106–107
combined with glatiramer acetate, 106
combined with methylprednisolone, 106
combined with mitoxantrone, 107
combined with natalizumab, 107–108
disease-modifying therapy, 96–97
International MS Genetics Consortium (IMSGC), 175
International Pediatric MS Study Group (IPMSSG), 6, 183, 187
2007 operational definitions, 11
definition of ADEM, 191
internuclear opthalmoplegia, 113–114
intravenous immunoglobulin use in acute MS relapses, 88–90
use in ADEM, 215
J-C virus, 63
Kawasaki syndrome
differential diagnosis, 68
Kearn–Sayre syndrome, 67
Kjer’s dominant optic atrophy, 225
Krabbe’s disease, 4
differential diagnosis, 66
Kurtzke’s Functional System (FS), 43
Langerhans cell histiocytosis
differential diagnosis, 68–69
Leber’s hereditary optic neuropathy (LHON), 67, 225–226
leukodystrophies
confusion with pediatric MS, 3–4
differential diagnosis, 66–67
Lhermitte’s phenomenon, 125
Lyme disease
differential diagnosis, 64
magnetic resonance imaging. See MRI magnetic resonance spectroscopy (MRS), 54
magnetization transfer imaging (MTR), 54
major histocompatibility complex (MHC), 173–175
Marie, Pierre, 1, 3, 4, 13
McDonald MRI criteria, 50–52
measles, 4
medical complaints unexplained, 150
mental health issues, 125
treatment and support, 129–130
metabolic polychromatineuropathy, 249
metachromatic leukodystrophy, 4
differential diagnosis, 66
methotrexate, 104
methylprednisolone, 105–106
ADEM treatment, 212–213
combined with interferon beta, 106
optic neuritis treatment, 228
repetition of ADEM treatment, 215
migraine
typical presentations, 68
migraine
role in pediatric MS, 24–25
migration studies
genetics of pediatric MS, 170
mitochondrial disorders
differential diagnosis, 67
mitoxantrone, 103
combined with interferon beta, 107
molecular genetic studies in pediatric MS, 173
monoclonal antibodies
breakthrough therapies, 104–105
monophasic ADEM, 187–189
motor function difficulties
ataxia, 119
coordination difficulties, 117
evaluation, 117–118
gait imbalance, 117
spasticity and weakness, 115, 118–119
symptomatic therapy, 115–119
tremor, 119
MRI
criteria for ADEM, 14
criteria for children, 14
criteria in operational definitions, 14
differential diagnosis difficulties, 14
MRI features of acute transverse myelitis (ATM), 247–248
MRI features of ADEM, 202–210
acute haemorrhagic leukoencephalitis (AHLE), 208
ADEM variants, 207–208
bi-stratal variant, 208
bi-halamic variant, 208
‘Dawson’s fingers’, 205
differential diagnosis of radiological ADEM, 209
diffusion weighted imaging, 210
eye studies, 203
gadolinium enhancement, 205–206
IPMSSG consensus definitions, 202
MRI features of ADEM (cont.)
lesion distribution, 206–207
lesion margins, 203–204
lesion number, 203
lesion regional involvement, 206–207
lesion shape, 204–205
lesion size, 203–204
lesion symmetry, 206
MR spectroscopy, 210
new imaging techniques, 210
new MRI diagnostic criteria for ADEM, 208–209
outcome of ADEM lesions, 209
periventricular perpendicular ovoid lesions, 204–205
presence of 'black holes', 205
role in diagnosis of ADEM, 202–203
spinal cord lesions, 207
T1-weighted characteristics (black holes), 205
timing of repeat imaging, 209
tumefactive 'tumor-like' lesions, 207
MRI features of neuromyelitis optica (NMO), 257–258
MRI features of optic neuritis, 228
MRI features of pediatric MS, 48–55
ADEM differential diagnosis, 53–54
applying adult MS criteria to children, 50–52
characteristics of pediatric MS, 48
'Dawson’s fingers', 205
differential diagnosis, 53–54
findings at onset, 77
findings in children with MS, 49–50
McDonald MRI criteria, 50–52
MRI protocol for MS, 48–49
non-conventional MRI methods, 54–55
pediatric criteria, 48
periventricular perpendicular ovoid lesions, 204–205
predictive value for diagnosis of pediatric MS, 52
presence of 'black holes', 205
prognostic value of MRI, 52–53
proposed MRI criteria for children, 52
radiologically isolated syndrome, 52
multiphasic ADEM, 187–189
multiple sclerosis. See pediatric MS, 4
mumps, 4
mycophenolate mofetil, 104
*Mycoplasma* infection
differential diagnosis, 64
atalizumab, 102–103
combined with interferon beta, 107–108
neoplasms
differential diagnosis, 65–66
neuroborreliosis
differential diagnosis, 64
neurocysticercosis
differential diagnosis, 65
neurofibromatosis, 65
neuromyelitis optica (NMO), 255–268
antibody testing, 260–261
aquaporin-4 (AQP4) autoimmunity, 255
differential diagnosis, 260
new MRI diagnostic criteria for NMO, 258
operational definitions, 255
immunopathology, 263
MRI features, 257–258
NMO IgG antibody, 255
doctoral treatment, 265
CSF findings, 260
demographic features, 256
diagnostic criteria, 256
differential diagnosis, 260
disease course, 262–263
future directions in research, 267–268
historical perspective, 255–256
immunopathology, 263
MRI features, 257–258
NMO IgG antibody, 255
non-conventional MRI methods, 54–55
neuroimaging, 228
neuro-ophthalmologic examination, 226–228
non-conventional MRI methods, 54–55
nystagmus, 114
MRI criteria for ADEM, 14
MS with an initial ADEM-like episode, 15
need for revision, 16
overlap in MRI criteria, 14
polyfocal presentation, 13–14
polyregional presentation, 13–14
polyfocal presentation, 13–14
polyfocal presentation, 13–14
presence of encephalopathy, 13
recurrent and multiphasic ADEM versus MS, 15–16
use of adult MS criteria in children, 10
validity of the proposed criteria, 12–13
optic neuritis, 212
operational definition, 10
optic neuritis in children, 213, 223–231
as symptom of MS, 226
as symptom of neuromyelitis optica, 226
clinical features, 223–225
corticosteroid treatment, 228
definition, 223
differential diagnosis, 225–228
etiology, 234
evaluation, 225–228
incidence and prevalence, 223
laboratory testing, 228
methylprednisolone treatment, 228
MRI features, 228
non-conventional MRI methods, 54–55
neuroimaging, 228
optical coherence tomography (OCT), 231
prognosis after optic neuritis in childhood, 228–231
recurrent optic neuritis, 234–241
risk of developing MS, 228–231
studies, 223
symptoms, 113
treatment, 228
use of disease-modifying therapy, 230–231
use of immunomodulator therapy, 230–231
Optic Neuritis Treatment Trial (ONTT), 223–225, 228
optic neuropathies, 225
optic pathway glioma
differential diagnosis, 65–66
optical coherence tomography (OCT) diagnostic use, 231
use in recurrent optic neuritis, 237–240

© in this web service Cambridge University Press
www.cambridge.org
pain
effects on cognitive functioning, 138
pain syndromes
symptomatic therapy, 124–126
papilledema, 226
paroxysmal symptoms
symptomatic therapy, 124–126
passive smoking as risk factor, 28
pathology of pediatric MS, 157–159
patient well-being, 144–154
children’s anxieties and fears, 144
difficulties faced by children and families, 144
health-related quality of life in MS, 144–146
improving well-being of children with MS, 153–154
psychosocial aspects of pediatric MS, 148–153
risk of mental health problems, 144
school and pediatric MS, 146–149
stress of chronic illness, 144
Peabody Developmental Motor Scale, 117
Pediatric Evaluation of Disability Inventory (PEDI), 117
pediatric MS
biological presentation, 157–164
breakthrough therapies, 101–109
clinical presentation, 36–45
cognitive dysfunction, 134–141
confusion with leukodystrophies, 3–4
corticosteroid treatment for relapses, 92–94
course of the disease, 75–84
disease-modifying therapy (DMT), 96–99
distinction from ADEM at onset, 4
distinction from recurrent or multiphasic ADEM, 15–16
epidemiology, 19–29
genetics, 169–177
influence of environmental factors, 79–80
influence of genetic factors, 79–80
initial reports of, 1–3
MRI features, 48–55
onset of disease. See course of the disease
operative definition, 11
patient well-being, 144–154
prognosis, 80–84
prognostic factors for secondary progression, 79
symptomatic therapy, 112–130
use of adult MS criteria, 10
use of IV immunoglobulin in acute relapses, 88–90
use of plasma exchange in acute relapses, 87–88
with an initial ADEM-like episode, 15
Pediatric Quality of Life Inventory (PedsQL), 145
PedsSQ Multidimensional Fatigue Scale, 128
Pelizaeus-Merzbacher disease, 4
differential diagnosis, 66
place imaging, 54
place of residence
and risk of pediatric MS, 24–25
plasma exchange
ADEM treatment, 215–217
use in acute MS relapses, 87–88
plasmapheresis. See plasma exchange
polyarteritis nodosa
differential diagnosis, 68
polyfocal presentation, 13–14
gene expression model, 170
polygenic threshold model, 170
polyregional presentation, 13–14
polysymptomatic presentation, 13–14
post-exanthematous encephalomyelitis. See ADEM
post-infectious encephalomyelitis. See ADEM
post-vaccinal encephalomyelitis. See ADEM
prednisolone, 105
prednisone treatment in ADEM, 212–213
progressive multifocal leukoencephalopathy
differential diagnosis, 63
proton magnetic resonance spectroscopy (MRS), 54
psychological distress
effects on cognitive functioning, 138
psychosocial aspects of pediatric MS, 148–153
accessing care, 153
building support, 152
disclosure of the diagnosis, 151–152
emotional health of the child/teen, 151
explaining to other people, 151–152
improving psychosocial function, 151–153
including the child/teen, 151
poor compliance with treatment, 150
psychosocial impact of pediatric MS, 148–150
risk taking behaviors, 151
school avoidance, 151
signs of psychosocial distress, 150–151
support groups, 152
transitioning to adult care, 153
unexplained medical complaints, 150
working with the family, 151
race
and pediatric MS risk, 24
radiologically isolated syndrome, 52
recurrent ADEM, 187–189
recurrent optic neuritis, 234–241
characteristics, 234–235
chronic recurrent inflammatory optic neuritis (CRION), 234–235
NMO-IgG antibodies, 236–237
optical coherence tomography (OCT), 237–240
pediatric studies, 235–236
therapy, 240
research on pediatric MS
future directions, 6
research update. See biology of pediatric MS
rheumatoid arthritis, 175
risk taking behaviors, 151
rituximab, 104–105
rubella, 4
sarcoidosis
differential diagnosis, 60–61
school and pediatric MS, 146–149
accommodations/interventions, 148
impact of cognitive dysfunction, 147
social-emotional functioning, 147
school avoidance, 151
scleroderma
differential diagnosis, 61
sensory symptoms
sympathomeric therapy, 124–126
Sjögren’s syndrome
differential diagnosis, 68
smallpox, 4
social-emotional functioning in school, 147
spasticity and weakness
non-pharmacologic treatment, 118
pharmacological management, 118–120
symptomatic therapy, 115
speech difficulties
evaluation and care of, 117
spinal cord lesions in ADEM, 207
support groups, 152
Susac syndrome
differential diagnosis, 68
susceptibility-weighted imaging (SWI), 54
swallowing difficulties
evaluation and care of, 117
Symbol Digit Modalities Test (Oral Version), 139
symptomatic therapy, 112–130
aims of, 112
ataxia and tremor, 119
autonomic symptoms, 119–122
bladder and bowel problems, 119–122
classification of symptoms, 112–113
depression, 129–130
fatigue, 128–129
heat intolerance, 125–128
mental health issues, 125, 129–130
motor function difficulties, 115–119
pain syndromes, 124–126
paroxysmal symptoms, 124–126
range of possible symptoms, 112
recognizing symptoms, 112
social and psychological support, 125
spasticity and weakness, 115, 118–119
speech difficulties, 117
swallowing difficulties, 117
symptom overlap in demyelinating disorders, 112–113
systemic symptoms, 125–130
unpredictable nature of symptoms, 112
visual abnormalities, 113–116
systemic inflammatory disorders
differential diagnosis, 58–61
systemic lupus erythematous (SLE) differential diagnosis, 58–60
systemic symptoms symptomatic therapy, 125–130
T cell responses in MS, 161–162
T1 and T2 relaxometry, 54
transitioning to adult care, 153
transverse myelitis (TM), 39, 213
operational definition, 10
See also acute transverse myelitis (ATM).
treatment
poor compliance with, 150
tremor and ataxia
symptomatic therapy, 119
Tropheryma whipplei bacillus, 64
tuberculosis
differential diagnosis, 62
tuberculous meningitis
differential diagnosis, 62
Uthoff’s phenomenon, 125
vaccinations, 28
vanishing white matter disease
differential diagnosis, 67
varicella zoster virus (VZV), 26, 27, 63
vascular disorders
differential diagnosis, 67–68
viral infections
and pediatric MS, 26–27
visual abnormalities
evaluation of visual function, 114
internuclear ophthalmoplegia, 113–114
management of visual dysfunction, 114–115
non-pharmacologic interventions, 114–115
nystagmus, 114
optic neuritis, 113
pharmacologic management, 115
symptomatic therapy, 113–116
vitamin D role in pediatric MS, 163
vitamin D response elements role in pediatric MS genetics, 174
Wegener’s granulomatosis
differential diagnosis, 68
Whipple’s disease
differential diagnosis, 64